STOCK TITAN

Avalon GloboCare Corp. - $ALBT STOCK NEWS

Welcome to our dedicated page for Avalon GloboCare news (Ticker: $ALBT), a resource for investors and traders seeking the latest updates and insights on Avalon GloboCare stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Avalon GloboCare's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Avalon GloboCare's position in the market.

Rhea-AI Summary
Avalon GloboCare Corp. announces the official launch of the KetoAir™ breathalyzer device and related accessories in the U.S. at the Hack Your Health by KetoCon 2024 Conference. The cutting-edge breathalyzer features AI-enabled software, nano-sensor-based technology, and FDA registration. The KetoAir™ breathalyzer allows users to assess ketosis status, record diet and exercise details, and receive personalized nutritional and exercise recommendations. The product aims to provide a holistic solution to monitor and optimize ketosis state and body fat burning rate, setting a new standard in the market. Consumers can purchase the KetoAir™ breathalyzer exclusively at KetoAir.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.38%
Tags
none
-
Rhea-AI Summary
Avalon GloboCare Corp. extends its exclusive distribution agreement with Qi Diagnostics to distribute the innovative KetoAir™ breathalyzer device for ketogenic health management. The device, equipped with AI-enabled software and nanosensor-based technology, offers personalized nutritional and exercise recommendations. Avalon aims to target the diabetes reversal and obesity management markets, with a soft launch planned for 2024 and a full-scale launch in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.79%
Tags
AI
-
Rhea-AI Summary
Avalon GloboCare Corp. (ALBT) partners with ChtrBx to develop a marketing launch plan for KetoAir™, a companion diagnostic and monitoring device for ketogenic dietary management. The pocket-sized breathalyzer provides accurate and instant results, and the company plans to soft launch in 2024 followed by a hard launch in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.13%
Tags
none
Rhea-AI Summary
Avalon GloboCare Corp. partners with Qi Diagnostics to co-develop international multi-center clinical studies for DKAir™ breathalyzer device for early detection of diabetic ketoacidosis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.67%
Tags
partnership clinical trial
-
Rhea-AI Summary
Avalon GloboCare Corp. launches the KetoAir™ mobile application in the Apple App store and Google Play store. The app is a companion diagnostic and monitoring device for ketogenic dietary management. The KetoAir™ breathalyzer device provides accurate and instant results, helping users monitor their ketone levels and optimize their ketosis state. The app also includes an AI nutritionist that offers personalized recommendations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
none
-
Rhea-AI Summary
Avalon GloboCare Corp. announces acquisition of Merlin Medical Supply and Leading Edge Innovations by Laboratory Services MSO, LLC
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
Rhea-AI Summary
Avalon GloboCare receives patent for QTY-Code modified cytokine and chemokine protein receptor molecules
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27%
Tags
none
-
Rhea-AI Summary
Avalon GloboCare Corp. announces new proprietary testing method for Tuberculosis diagnosis, expected to generate revenue in 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.57%
Tags
none
-
Rhea-AI Summary
Avalon GloboCare Corp. opens new lab in Arizona, engages former Congressman Barry M. Goldwater Jr. to expand insurance coverage and grow lab footprint
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
Avalon GloboCare Corp.

Nasdaq:ALBT

ALBT Rankings

ALBT Stock Data

2.99M
4.77M
56.53%
1.43%
0.76%
General Medical and Surgical Hospitals
Health Care and Social Assistance
Link
United States of America
FREEHOLD